Pembrolizumab biosimilar - Amgen
Alternative Names: ABP-234Latest Information Update: 11 Oct 2024
At a glance
- Originator Amgen
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Non-small cell lung cancer
Most Recent Events
- 12 Sep 2024 Phase-III clinical trials in Non-small cell lung cancer (Early-stage disease, Adjuvant therapy) in Bulgaria, Poland, Spain, Serbia, Italy, Chile (IV) (NCT06430866)
- 31 May 2024 Amgen plans a phase III trial for Non small cell lung cancer (Adjuvant treatment) (IV, Injection) in July 2024 (NCT06430866)
- 19 Mar 2024 Amgen plans a phase III trial for Non-Small Cell Lung Cancer (Late-stage disease, Metastatic disease, First line therapy) in March 2024 (IV) (NCT06311721) .